Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | SLC6A7 | Q99884 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82864 | 0.84 | DHFR (0.39) | GRM1ADORA2AADORA1KDM4EGSK3B | |
| SCHEMBL17477187 | 0.78 | DRD4 (0.38) | GRM1ADORA2AADORA1DRD4DRD2 | |
| SCHEMBL17538367 | 0.78 | ADRB1 (0.51) | SLC6A7KDM4E | |
| SCHEMBL17538377 | 0.78 | ADRB1 (0.51) | SLC6A7KDM4E | |
| SCHEMBL20159117 | 0.77 | GRM1 (0.49) | GRM1SLC6A7LMNAKDM4EMDM2 | |
| SCHEMBL19035624 | 0.77 | GRM1 (0.49) | GRM1SLC6A7LMNAKDM4EMDM2 | |
| SCHEMBL28780930 | 0.76 | PIK3CD (0.40) | GRM1SLC6A7CHRM1 | |
| SCHEMBL28780933 | 0.76 | CHRM1 (0.41) | GRM1KDM4ECHRM4CHRM1 | |
| SCHEMBL64037 | 0.76 | OGA (0.43) | DRD4DRD2CHRM4 | |
| SCHEMBL15025099 | 0.76 | GRM1 (0.48) | GRM1SLC6A7LMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | GRM1 3550/4885SLC6A7 485/4885ADORA2A 4328/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | GRM1 2839/4885SLC6A7 950/4885ADORA2A 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.